Index RUT
P/E -
EPS (ttm) -2.65
Insider Own 7.90%
Shs Outstand 48.72M
Perf Week 12.03%
Market Cap 759.86M
Forward P/E -
EPS next Y -3.32
Insider Trans -0.79%
Shs Float 45.27M
Perf Month 10.11%
Income -144.73M
PEG -
EPS next Q -0.73
Inst Own 88.63%
Short Float 15.39%
Perf Quarter 64.99%
Sales 80.89M
P/S 9.39
EPS this Y -15.95%
Inst Trans -5.49%
Short Ratio 7.70
Perf Half Y 148.15%
Book/sh 3.43
P/B 4.50
EPS next Y -8.08%
ROA -42.39%
Short Interest 6.97M
Perf Year 52.62%
Cash/sh 4.96
P/C 3.11
EPS next 5Y -
ROE -65.37%
52W Range 4.22 - 18.12
Perf YTD 49.81%
Dividend Est. -
P/FCF -
EPS past 5Y -59.00%
ROI -75.94%
52W High -14.68%
Beta 2.00
Dividend TTM -
Quick Ratio 2.86
Sales past 5Y 27.29%
Gross Margin 82.24%
52W Low 266.35%
ATR (14) 1.42
Dividend Ex-Date -
Current Ratio 2.86
EPS Y/Y TTM 24.89%
Oper. Margin -194.51%
RSI (14) 55.49
Volatility 12.98% 9.59%
Employees 284
Debt/Eq 0.17
Sales Y/Y TTM 94.02%
Profit Margin -178.93%
Recom 1.36
Target Price 24.73
Option/Short Yes / Yes
LT Debt/Eq 0.13
EPS Q/Q -0.31%
Payout -
Rel Volume 2.79
Prev Close 16.74
Sales Surprise -3.20%
EPS Surprise 2.01%
Sales Q/Q 30.74%
Earnings Apr 10 BMO
Avg Volume 904.79K
Price 15.46
SMA20 7.75%
SMA50 23.97%
SMA200 67.50%
Trades
Volume 2,523,766
Change -7.65%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-26-23 Resumed
Oppenheimer
Outperform
$25
Mar-09-23 Initiated
Barclays
Overweight
$20
Feb-28-23 Initiated
Oppenheimer
Outperform
$25
Oct-11-22 Initiated
Morgan Stanley
Equal-Weight
$11
May-31-22 Upgrade
Wells Fargo
Equal Weight → Overweight
$25
Feb-10-22 Initiated
Wells Fargo
Equal Weight
$28
Dec-29-21 Initiated
H.C. Wainwright
Buy
$62
Oct-14-21 Initiated
SVB Leerink
Outperform
$50
Jun-04-21 Resumed
Robert W. Baird
Outperform
$45 → $46
Apr-30-21 Resumed
Piper Sandler
Overweight
$60
Apr-30-21 Initiated
RBC Capital Mkts
Outperform
$42
Apr-14-21 Initiated
Berenberg
Buy
Nov-19-20 Initiated
Robert W. Baird
Outperform
$40
Aug-18-20 Initiated
Stifel
Buy
$34
Aug-18-20 Initiated
Piper Sandler
Overweight
$40
Aug-18-20 Initiated
Needham
Buy
$35
Aug-18-20 Initiated
JP Morgan
Overweight
$35
Show Previous Ratings
Apr-11-24 11:38PM
04:00PM
Apr-10-24 11:53AM
09:29AM
08:31AM
08:10AM
Loading…
08:10AM
07:00AM
Apr-09-24 01:15PM
07:00AM
Apr-03-24 07:00AM
Apr-02-24 07:00AM
Mar-25-24 07:00AM
Mar-20-24 09:40AM
Mar-11-24 07:00AM
Mar-06-24 04:00PM
04:30PM
Loading…
Mar-05-24 04:30PM
Feb-23-24 06:20AM
Feb-16-24 07:04PM
Feb-15-24 05:10PM
04:00PM
Feb-01-24 04:01PM
10:01AM
Jan-16-24 04:01PM
Jan-08-24 07:00AM
Jan-02-24 04:01PM
Dec-21-23 05:01PM
Dec-13-23 04:32PM
Dec-11-23 12:00PM
Dec-04-23 04:01PM
Nov-07-23 04:01PM
09:00AM
Loading…
Nov-02-23 09:00AM
Nov-01-23 04:01PM
Oct-18-23 09:35AM
Oct-14-23 06:01AM
Oct-12-23 05:15PM
04:01PM
Oct-11-23 07:09AM
Oct-05-23 09:35AM
Oct-04-23 09:35AM
Sep-28-23 10:00AM
Sep-20-23 09:30AM
Sep-15-23 12:00PM
09:55AM
Sep-11-23 12:10PM
Sep-08-23 05:32AM
Sep-07-23 07:00AM
Aug-31-23 10:12PM
04:01PM
Aug-02-23 05:01AM
Jul-24-23 09:55AM
Jul-15-23 08:12AM
Jul-13-23 05:15PM
04:01PM
Jul-11-23 10:00AM
Jun-29-23 10:00AM
Jun-14-23 07:00AM
May-25-23 06:28AM
May-24-23 09:55AM
May-09-23 04:01PM
May-04-23 09:55AM
Apr-19-23 06:05AM
Apr-18-23 09:55AM
Apr-17-23 02:30PM
Apr-13-23 05:15PM
04:01PM
Apr-11-23 04:01PM
Mar-30-23 10:00AM
Mar-21-23 10:05AM
03:49AM
Mar-20-23 12:17PM
09:00AM
08:30AM
Mar-17-23 09:22AM
Mar-14-23 04:45PM
Mar-06-23 04:01PM
Feb-27-23 11:57AM
Feb-09-23 05:35PM
04:15PM
Feb-08-23 04:01PM
Jan-09-23 09:55AM
08:35AM
Jan-04-23 07:01AM
Dec-28-22 09:35AM
Dec-15-22 04:01PM
Dec-12-22 05:30PM
08:09AM
Dec-07-22 04:01PM
Nov-10-22 09:00AM
09:00AM
Nov-04-22 09:55AM
Nov-03-22 09:00AM
Nov-02-22 04:01PM
Oct-26-22 07:00AM
Oct-19-22 10:57PM
09:00AM
Oct-08-22 08:30AM
Oct-06-22 05:15PM
04:01PM
Oct-05-22 08:00AM
Sep-20-22 09:48AM
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rape, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
van Houte Hans Chief Financial Officer Feb 16 '24 Sale 10.02 6,812 68,223 68,333 Feb 16 07:20 PM van Houte Hans Chief Financial Officer Jan 30 '24 Option Exercise 0.00 4,886 0 76,816 Jan 30 06:53 PM Hansen Gwenn Chief Scientific Officer Jan 30 '24 Option Exercise 0.00 5,207 0 38,736 Jan 30 06:52 PM Ring Christine Chief Legal Officer Jan 30 '24 Option Exercise 0.00 3,924 0 19,187 Jan 30 06:52 PM Hansen Gwenn Chief Scientific Officer Jan 30 '24 Sale 7.99 2,334 18,649 36,402 Jan 30 06:52 PM Ring Christine Chief Legal Officer Jan 30 '24 Sale 7.99 1,760 14,063 17,427 Jan 30 06:52 PM van Houte Hans Chief Financial Officer Jan 30 '24 Sale 7.99 1,671 13,352 75,145 Jan 30 06:53 PM van Houte Hans Chief Financial Officer Dec 20 '23 Sale 10.00 3,541 35,421 71,930 Dec 21 05:19 PM van Houte Hans Chief Financial Officer Dec 19 '23 Sale 10.00 10,906 109,093 75,471 Dec 20 04:55 PM Hansen Gwenn Chief Scientific Officer Oct 31 '23 Sale 5.20 1,633 8,487 33,529 Nov 01 04:40 PM Ring Christine Chief Legal Officer Oct 31 '23 Sale 5.20 1,232 6,403 15,263 Nov 01 04:40 PM van Houte Hans Chief Financial Officer Oct 31 '23 Sale 5.20 1,080 5,613 86,377 Nov 01 04:41 PM van Houte Hans Chief Financial Officer Oct 30 '23 Option Exercise 0.00 4,886 0 87,457 Nov 01 04:41 PM Hansen Gwenn Chief Scientific Officer Oct 30 '23 Option Exercise 0.00 5,207 0 35,162 Nov 01 04:40 PM Ring Christine Chief Legal Officer Oct 30 '23 Option Exercise 0.00 3,924 0 16,495 Nov 01 04:40 PM Hansen Gwenn Chief Scientific Officer Jul 31 '23 Sale 9.65 1,884 18,189 29,955 Aug 01 04:26 PM Ring Christine General Counsel Jul 31 '23 Sale 9.65 1,420 13,710 12,544 Aug 01 04:27 PM van Houte Hans Chief Financial Officer Jul 31 '23 Sale 9.65 1,245 12,020 82,571 Aug 01 04:28 PM van Houte Hans Chief Financial Officer Jul 30 '23 Option Exercise 0.00 4,886 0 83,816 Aug 01 04:28 PM Ring Christine General Counsel Jul 30 '23 Option Exercise 0.00 3,924 0 13,964 Aug 01 04:27 PM Hansen Gwenn Chief Scientific Officer Jul 30 '23 Option Exercise 0.00 5,207 0 31,839 Aug 01 04:26 PM Hansen Gwenn Chief Scientific Officer May 01 '23 Sale 9.88 1,136 11,219 26,632 May 02 04:31 PM van Houte Hans Chief Financial Officer May 01 '23 Sale 9.88 721 7,121 78,930 May 02 04:33 PM Ring Christine General Counsel May 01 '23 Sale 9.88 682 6,736 10,040 May 02 04:32 PM Wolff Stefani EVP and COO May 01 '23 Sale 9.88 342 3,378 6,113 May 02 04:33 PM van Houte Hans Chief Financial Officer Apr 30 '23 Option Exercise 0.00 2,886 0 79,651 May 02 04:33 PM Ring Christine General Counsel Apr 30 '23 Option Exercise 0.00 1,924 0 10,722 May 02 04:32 PM Wolff Stefani EVP and COO Apr 30 '23 Option Exercise 0.00 962 0 6,455 May 02 04:33 PM Hansen Gwenn Chief Scientific Officer Apr 30 '23 Option Exercise 0.00 3,206 0 27,768 May 02 04:31 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite